Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1351 AL 1365

[Quantitative evaluation of SPECT with FP-CIT. Importance of the reference area]

Ortega Lozano SJ, Martinez Del Valle Torres MD, Ramos Moreno E, Sanz Viedma S, Amrani Raissouni T, Jiménez-Hoyuela JM.

Rev Esp Med Nucl. 2010 Sep-Oct;29(5):246-50. doi: 10.1016/j.remn.2010.03.006. Epub 2010 Jul 23.

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D.

Neurobiol Dis. 2010 Nov;40(2):460-6. doi: 10.1016/j.nbd.2010.07.008. Epub 2010 Jul 23.

High-content screening of small compounds on human embryonic stem cells

Barbaric I, Gokhale PJ, Andrews PW.

Biochem Soc Trans. 2010 Aug;38(4):1046-50. doi: 10.1042/BST0381046.

Control of assembly and function of glutamate receptors by the amino-terminal domain

Hansen KB, Furukawa H, Traynelis SF.

Mol Pharmacol. 2010 Oct;78(4):535-49. doi: 10.1124/mol.110.067157. Epub 2010 Jul 21.

Physical activities and future risk of Parkinson disease

Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, Chen H.

Neurology. 2010 Jul 27;75(4):341-8. doi: 10.1212/WNL.0b013e3181ea1597.

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures

Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51. doi: 10.1017/S1461145710000775. Epub 2010 Jul 22.

Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia?

Zoccolella S, Lamberti SV, Iliceto G, Santamato A, Lamberti P, Logroscino G.

Curr Med Chem. 2010;17(28):3253-61. doi: 10.2174/092986710792232012.

Patient perception of dyskinesia in Parkinson's disease

Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1112-5. doi: 10.1136/jnnp.2009.173286. Epub 2010 Jul 28.

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia

Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, Liu E, Donkervoort S, Zheng JG, Shi Y, Ahmeti KB, Brooks B, Engel WK, Siddique T.

Neurology. 2010 Aug 31;75(9):807-14. doi: 10.1212/WNL.0b013e3181f07e0c. Epub 2010 Jul 28.

REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century

Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF.

Neurology. 2010 Aug 10;75(6):494-9. doi: 10.1212/WNL.0b013e3181ec7fac. Epub 2010 Jul 28.

Early diagnosis in Parkinson's disease: fact or fiction?

Jost W.

Neurodegener Dis. 2010;7(5):283. doi: 10.1159/000314722. Epub 2010 Jul 9.

[Pathologic gambling as an adverse effect of the treatment for Parkinson's disease]

Miranda M, Slachevsky A, Bustamante L, Pérez C.

Rev Med Chil. 2010 Apr;138(4):521-2. Epub 2010 Jun 30.

Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study

Nicoletti A, Pugliese P, Nicoletti G, Arabia G, Annesi G, Mari MD, Lamberti P, Grasso L, Marconi R, Epifanio A, Morgante L, Cozzolino A, Barone P, Torchia G, Quattrone A, Zappia M.

Mov Disord. 2010 Oct 30;25(14):2387-94. doi: 10.1002/mds.23297.

Characteristics of the sequence effect in Parkinson's disease

Kang SY, Wasaka T, Shamim EA, Auh S, Ueki Y, Lopez GJ, Kida T, Jin SH, Dang N, Hallett M.

Mov Disord. 2010 Oct 15;25(13):2148-55. doi: 10.1002/mds.23251.

Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment

Espay AJ, Paviour DC, O'Sullivan JD, Schmidt RE, Revilla FJ, Metman LV.

Mov Disord. 2010 Sep 15;25(12):1860-7. doi: 10.1002/mds.23194.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias